CRO & Sponsors

Partner With Us

At Headlands Research, we focus on ease of study start-up, delivery of the highest quality data, specialty/diverse patient access and expert patient retention for our CRO and Sponsor partners.

Fully owned Clinical Research Sites

  • 500+ expert clinical research professionals spanning across the United States and Canada
  • Embedded and dedicated site models allow maximum subject access
  • Engaged KOLs and specialists for protocol review and feasibility input
  • ICH GCP trained clinical staff
  • Entirely electronic sites (eSource, eRegulatory, etc.) which provide our Sponsors/CROs with real-time access to study data
  • Referral and EHR access through proprietary partnerships with large multi-specialty practices
  • 5,000+ completed Phase I – IV studies

Integrated Model

  • Centralized management and services team allows for a single point of contact during the feasibility, budgeting/contacting, start-up, etc. on your study
  • Centralized operations to ensure consistency and performance
  • Priority focus on quality data, expedited study start-up and patient retention

The Headlands Research Difference

We deliver of the highest quality data and patient access.

Our patient access:

  • Site and physician partnership databases
  • Unique access to diverse and specialty populations
  • Hispanic/Latino
  • African American
  • Elderly (over 65+ years old)
  • Pediatric and adolescent (under 18 years old)
  • Large database(s) of healthy volunteers
  • Clinical research centers located in large metropolitan areas with access to millions of potential patients

Advance Clinical Trials With Us

Choosing the correct sites is crucial to the success of your trial. Headlands Research sites are committed to efficient study start up, expedited enrollment and production of the highest quality data – all with the ease of a single point of contact. Please consider Headlands Research for your next trial:

Connect With Us

Name(Required)
This field is for validation purposes and should be left unchanged.